Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Rating Change

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was cut by Wells Fargo from “Outperform” rating to “Market Perform” rating in a research note revealed to investors and clients on Wednesday morning.

The stock rating downgrade was noticed by equity trades, as NASDAQ:REGN is currently trading -3.99% lower at $397.26 as of 09:32 New York time. Regeneron Pharmaceuticals Inc.’s stock is down -19.04% over the past 200 days. It has underperformed the Standard & Poor’s 500 index, which has increased 1.16% over the same time.

Out of 21 analysts covering Regeneron Pharmaceuticals Inc., 14 rate it a Buy, 11 indicate a Hold while 1 suggest a Sell. The highest target is $668 and the lowest is $325 according to Thomson/First Call. The 12-month mean target is $475.76, which means upside potential of 19.76% over the current price.

NASDAQ:REGN Price Chart & Trend

The stock price of Regeneron Pharmaceuticals Inc. has declined 19.04% over the last 200 days, and is in strong down trend. In the last 50 and 100 days, Regeneron Pharmaceuticals Inc. is up 4.33% and down 27.52%, respectively. Our stocks momentum model is shown on the price chart below.

Source: RightEdge Systems, Yahoo Split & Dividend Adjusted Data and OctaFinance Trading Models

Institutional Ownership

Lagoda Investment Management L.P. had the most significant stake with ownership of 100,155 shares as of q2 2015 for 13.39% of the US long equity exposure. Jw Asset Management Llc is another very bullish active investment manager who is possessing 48,619 shares of Regeneron Pharmaceuticals Inc. or 7.54% of their US long equity exposure. Moreover, March Altus Capital Management Lp have 6.8% of their US long equity exposure invested in the company for 2,294 shares. The Florida-based fund Polen Capital Management Llc disclosed it had purchased a stake worth about 5.48% of the active investment manager’s stock portfolio in Regeneron Pharmaceuticals Inc.. The Virginia-based fund Sands Capital Management Llc is also positive about the stock, possessing 554,959 shares or 5.29% of their US long equity exposure.Over the last 6 months, Regeneron Pharmaceuticals Inc. NASDAQ:REGN has seen 0 buying transactions, and 12 insider sales. The net result was for 12 transactions, worth $103.45M.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Profile

Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) traded down -3.99% on 20 April, hitting $397.26. A total of 603,207 shares of the company’s stock traded hands. This is down from average of 1.05M shares. Regeneron Pharmaceuticals Inc. has a 52 week low of $348.96 and a 52 week high of $605.93. The company has a market cap of $40.78B and a P/E ratio of 72.11.

Get the latest Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Wells Fargo Lowers Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Rating to “Market Perform” from “Outperform” appeared first on Octafinance.